retifanlimab,docetaxel
incyte,aventis,sanofi
['retifanlimab', 'docetaxel', 'sarcoma']
 #sarcoma poster discussion session at #asco2022 abs 11516 safety analyses of pd-1 inhibitor #retifanlimab with #gemcitabine &amp; #docetaxel show general safety &amp; good tolerability: most common treatment related grade 3 ae = anemia in 69.2% of the pts with no grade 4 ae #meded
Independent & international experts in #Sarcoma. #MedEd communicators, keeping you up to date with research & medical news in Sarcoma. Part of https://t.co/qM8Tca8PQX